{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:43:36Z","timestamp":1791089016534,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003459.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000}}],"reference-count":47,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003459.pub4","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T17:04:16Z","timestamp":1407344656000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Methotrexate for induction of remission in refractory Crohn's disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"John WD","family":"McDonald","sequence":"first","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tsoulis","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"10.1002\/14651858.CD003459.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Digestive and Liver Disease"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD003459.pub4-BIB0002|cit2","first-page":"A662","article-title":"Controlled trial comparing intravenous methotrexate and oral azathioprine for chronic active Crohn's disease: preliminary report","volume":"116","author":"Ardizzone","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0003|cit3","first-page":"295","article-title":"Controlled trial comparing intravenous methotrexate and oral azathioprine for chronic active Crohn's disease: preliminary report","volume":"23","author":"Bianchi Porro","year":"1982","journal-title":"Gut"},{"issue":"27","key":"10.1002\/14651858.CD003459.pub4-BIB0004|cit4","first-page":"1724","article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD003459.pub4-BIB0005|cit5","first-page":"A591","article-title":"A double blind, randomized, placebo-controlled trial of methotrexate in Crohn's disease","volume":"102","author":"Arora","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0006|cit6","first-page":"A121","article-title":"A multicentre trial of methotrexate (MTX) for chronically active Crohn's disease (CD)","volume":"35 Suppl 4","author":"Feagan","year":"1994","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD003459.pub4-BIB0008|cit8","first-page":"A745","article-title":"A multicentre trial of methotrexate (MTX) treatment for chronically active Crohn's disease","volume":"106","author":"The North American Crohn's Study Group Investigators","year":"1994","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2008.05.061","article-title":"A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003459.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Feagan BG McDonald JWD Panaccione R Enns R Bernstein CN Ponich T A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease United European Gastroenterology Week Vienna, Austria 2008","DOI":"10.1053\/j.gastro.2008.05.061"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0012|cit12","first-page":"A132","article-title":"Methotrexate and 6-mercaptopurine in steroid-dependent inflammatory bowel disease patients: a randomized controlled clinical trial","volume":"45","author":"Hermida","year":"1999","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mat\u00e9-Jim\u00e9nez","year":"2000","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0014|cit14","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD003459.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study","volume":"18","author":"Schr\u00f6der","year":"2006","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub4-BIB0016|cit16","first-page":"A659","article-title":"The efficacy of long term intramuscular methotrexate in difficult to treat Crohn's disease","volume":"136","author":"Clark","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003459.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MCG.0b013e31802e6875","article-title":"Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice","volume":"42","author":"Dom\u00e8nech","year":"2008","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1046\/j.1365-2036.1999.00667.x","article-title":"A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis","volume":"13","author":"Egan","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003459.pub4-BIB0019|cit19","first-page":"A227","article-title":"A randomized, single-blind, pharmacokinetic and doseresponse study of subcutaneous methotrexate, 15 and 25 mg\/week, for refractory ulcerative colitis and Crohn's disease","volume":"114","author":"Egan","year":"1998","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1002\/14651858.CD003459.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North AmericanCrohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD003459.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/00042737-200509000-00002","article-title":"Methotrexate for Crohn's disease: experience in a district general hospital","volume":"17","author":"Hayee","year":"2005","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0022|cit22","first-page":"2552","article-title":"Methotrexate as possible treatment of refractory chronic inflammatory bowel disease","volume":"138","author":"Houben","year":"1992","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2036.2003.01614.x","article-title":"Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease","volume":"18","author":"Kurnik","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD003459.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2010.04569.x","article-title":"Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab","volume":"33","author":"Laharie","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0025|cit25","first-page":"61","article-title":"Methotrexate in patients with Crohn\u2019s disease: a regional experience","volume":"26","author":"Lampen-Smith","year":"2011","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0026|cit26","first-page":"1730","article-title":"Methotrexate in Crohn's disease: long-term efficacy and toxicity","volume":"95","author":"L\u00e9mann","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD003459.pub4-BIB0027|cit27","first-page":"457","article-title":"Methotrexate in therapy of chronic inflammatory bowel diseases","volume":"34","author":"Schr\u00f6der","year":"1996","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"2","key":"10.1002\/14651858.CD003459.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2036.2011.04925.x","article-title":"Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience","volume":"35","author":"Suares","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD003459.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/01.mcg.0000177249.46130.a3","article-title":"Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand","volume":"39","author":"Sun","year":"2005","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003459.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apt.12161","article-title":"Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease","volume":"37","author":"Wilson","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD003459.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1200\/JCO.1988.6.12.1882","article-title":"Pharmacokinetics of subcutaneous methotrexate","volume":"6","author":"Balis","year":"1988","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD003459.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/BF01296109","article-title":"Low-dose oral methotrexate in refractory inflammatory bowel disease","volume":"38","author":"Baron","year":"1993","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","article-title":"Prognosis in Crohn's disease - based on result from a regional patient group from the country of Copenhagen","volume":"26","author":"Binder","year":"1985","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.1780330112","article-title":"Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis","volume":"33","author":"Brooks","year":"1990","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD003459.pub4-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545.pub4","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","article-title":"Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease","volume":"65","author":"Egan","year":"1999","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003459.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatology"},{"issue":"7650","key":"10.1002\/14651858.CD003459.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"8167","key":"10.1002\/14651858.CD003459.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0040|cit40","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD003459.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003459.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD003459.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/rheumatology\/39.7.812","article-title":"Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription","volume":"39","author":"Lorenzi","year":"2000","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003459.pub4-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000297.pub2","article-title":"Cyclosporine for induction of remission in Crohn's disease","author":"McDonald","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003459.pub4-BIB0045|cit45","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD003459.pub4-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003459.pub2","article-title":"Methotrexate for induction of remission in refractory Crohn\u2019s disease","author":"Alfadhli","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD003459.pub4-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003459.pub3","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"McDonald","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003459.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T11:51:18Z","timestamp":1711713078000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003459.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003459.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}